Maybe to start off, what are some of the key elements of trial design that clinicians need to understand to actually interpret these studies correctly and translate them to the real world?

Yeah, so it's a good question.

We used to see back many years ago week 12 as a primary endpoint time, and that's gone away, and almost everything has been week 16.

So week 16, primary endpoint, very typical for psoriasis.

It's also kind of emerged as the primary endpoint for most eczema trials.

We do have a couple, the... recent eczema trials with a week 24 endpoint.

This compares to, let's say, alopecia areata where you need more time.

It's the next part where I'm like, what are these patient year nonsense?